Cargando…
p73 as a Pharmaceutical Target for Cancer Therapy
About half of all human tumors contain an inactivating mutation of p53, while in the remaining tumors, the p53 pathway is frequently abrogated by alterations of other components of its signaling pathway. In humans, the p53 tumor suppressor is part of a small gene family that includes two other membe...
Autores principales: | Bisso, Andrea, Collavin, Licio, Del Sal, Giannino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267157/ https://www.ncbi.nlm.nih.gov/pubmed/21391908 http://dx.doi.org/10.2174/138161211795222667 |
Ejemplares similares
-
Mutant p53 as a guardian of the cancer cell
por: Mantovani, Fiamma, et al.
Publicado: (2018) -
The rebel angel: mutant p53 as the driving oncogene in breast cancer
por: Walerych, Dawid, et al.
Publicado: (2012) -
Complexes formed by mutant p53 and their roles in breast cancer
por: Bellazzo, Arianna, et al.
Publicado: (2018) -
Cutting the Brakes on Ras—Cytoplasmic GAPs as Targets of Inactivation in Cancer
por: Bellazzo, Arianna, et al.
Publicado: (2020) -
Wild-type and mutant p53 in cancer-related ferroptosis. A matter of stress management?
por: Corazzari, Marco, et al.
Publicado: (2023)